Navigation Links
Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404

LONDON and FLORENCE, Italy - 8 March 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces positive initial findings from its second, confirmatory phase II trial of AS1404 in non-small cell lung cancer.

This 30-patient trial tested an 1800 mg/m2 dose of AS1404 in combination with carboplatin and paclitaxel chemotherapy. Investigators reported a response rate of 50%. A further 43% of patients showed disease stabilisation, while only 7% had progressive disease as their best response. Addition of AS1404 to chemotherapy was well-tolerated despite the use of a dose 50% higher than that used in previous combination studies.

The data are included in a presentation made today at the Tumor Microenvironment meeting in Florence, Italy, by Antisoma's Chief Medical Officer, Dr Gary Acton. Further data from the trial, including time to progression and survival findings, are expected during the second half of this year.

An earlier randomised controlled phase II study in lung cancer showed a 5-month increase in median survival when 1200 mg/m2 AS1404 was added to carboplatin and paclitaxel. Initial data from other controlled phase II trials in ovarian and prostate cancers have shown increased response rates with addition of AS1404 to standard chemotherapy.

Dr Mark McKeage of the University of Auckland, New Zealand, a key investigator in both AS1404 lung cancer studies, said: "The high response rate and favourable tolerability profile in this study support earlier data suggesting that AS1404 has real potential as a novel therapy for lung cancer."

Glyn Edwards, CEO of Antisoma, added: "AS1404 now draws support from four phase II studies across three different cancers, an excellent position to be in as we prepare the drug for phase III trials."

Enquiries: Daniel Elger, Director of Communications +44 (0)7909 915 068 Antisoma plc

Mark Court/Lisa Baderoon/
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Data supporting three Antisoma programmes presented at AACR
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
8. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma plc Second lung cancer trial adds positive data
(Date:7/30/2015)...  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... of our Medicare resources and continue highlighting the success of the prescription drug benefit, ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... biopharmaceutical company at the forefront of immunology treatment and research, ... in Washington, D.C. by reinforcing its commitment to improving the ... meeting, a large body of UCB data will highlight the ... severe Crohn,s disease. "ACG is an opportunity for ...
... MILPITAS, Calif., Oct. 28, 2011 LifeScan, Inc., the maker ... with Rite Aid to launch the Rite Track ... of American Diabetes Month, a mobile bus will travel to ... to provide complimentary on-site blood glucose and A1c testing, educational ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 2UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 3Celebrity Chef Sam Talbot Gets on Board for Diabetes Testing 2Celebrity Chef Sam Talbot Gets on Board for Diabetes Testing 3Celebrity Chef Sam Talbot Gets on Board for Diabetes Testing 4
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... new industry players to know in predictive health analytics , Jvion continues ... technologies. The firm creates predictive software that targets patient and population level illness ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... M3 USA ... excited to launch three new Board Exam Courses. , The additions of Gastroenterology, ... Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Well-known for its ... offering wedding cakes with custom designs, making life just a little bit ... designed wedding cakes for each customer who orders one. , The bakery provides a ...
(Date:7/31/2015)... Alexandria, VA (PRWEB) , ... July 31, 2015 ... ... Mesothelioma is a one-day event geared to patients and family members, medical professionals, ... local and regional mesothelioma experts. The conference is a collaborative effort between the ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
... Device "Rewires" Brain, Improves and Restores Balance, Normal Walking , ... ... on, "virtual reality" has a whole new meaning for people with ... walk normally again., , , , ,The GaitAid Virtual Walker, a ...
... spring , , SATURDAY, May 16 (HealthDay News) -- Spring ... them, especially if you have asthma. , Pollen from ... trigger that sufferers must learn to cope with this ... Center at Brigham and Women,s Hospital in Boston. Other ...
... Women Find the Solutions to their Infertility Issues by Bridging the ... ... (PRWEB) May 16, 2009 -- National Fertility Link ... to be pregnant. National Fertility Link helps Infertile couples find the ...
... Dr. Gary L. Gottlieb, President of Brigham and Women,s ... Hill Community College,s 35th commencement exercises, on Saturday, ... proponent of alleviating mental health care disparities, will receive ... his outstanding commitment and service to the College. "Dr. ...
... (the "Company") today announced its operating results for the first ... Our net patient service revenue increased by $6.2 million, ... to $95.0 million from $88.8 million for the comparable period ... or 4.2%, less than the same period in 2008, while ...
... chances of macular degeneration , , FRIDAY, May 15 (HealthDay News) ... your eyes as well as the rest of your body, ... vitamins C and E, zinc, lutein, zeaxanthin, omega-3 fatty acids ... low-glycemic index foods) can lower the risk of developing age-related ...
Cached Medicine News:Health News:New Hope for Walking Normally, Living Better With Cerebral Palsy 2Health News:Know Your Asthma Triggers 2Health News:Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics 2Health News:Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics 3Health News:Healthcare Leader Dr. Gary Gottlieb Keynotes Commencement 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 3Health News:LifeCare Holdings, Inc. Announces First Quarter Results 4Health News:LifeCare Holdings, Inc. Announces First Quarter Results 5Health News:LifeCare Holdings, Inc. Announces First Quarter Results 6Health News:LifeCare Holdings, Inc. Announces First Quarter Results 7Health News:LifeCare Holdings, Inc. Announces First Quarter Results 8Health News:LifeCare Holdings, Inc. Announces First Quarter Results 9Health News:LifeCare Holdings, Inc. Announces First Quarter Results 10Health News:Nutrient-Rich Diet Lowers Risk of Age-Related Eye Disease 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: